Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study.
Janssens R, Lang T, Vallejo A, Galinsky J, Plate A, Morgan K, Cabezudo E, Silvennoinen R, Coriu D, Badelita S, Irimia R, Anttonen M, Manninen RL, Schoefs E, Vandebroek M, Vanhellemont A, Delforge M, Stevens H, Simoens S, Huys I. Janssens R, et al. Among authors: silvennoinen r. Front Med (Lausanne). 2021 Jul 6;8:686165. doi: 10.3389/fmed.2021.686165. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34295912 Free PMC article.
S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.
Liu M, Wang Y, Miettinen JJ, Kumari R, Majumder MM, Tierney C, Bazou D, Parsons A, Suvela M, Lievonen J, Silvennoinen R, Anttila P, Dowling P, O'Gorman P, Tang J, Heckman CA. Liu M, et al. Among authors: silvennoinen r. Front Cell Dev Biol. 2021 Aug 16;9:723016. doi: 10.3389/fcell.2021.723016. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34485305 Free PMC article.
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Majumder MM, et al. Among authors: silvennoinen r. Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915594 Free PMC article.
Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.
Luoma S, Silvennoinen R, Rauhala A, Niittyvuopio R, Martelin E, Lindström V, Heiskanen J, Volin L, Ruutu T, Nihtinen A. Luoma S, et al. Among authors: silvennoinen r. Ann Hematol. 2021 Jun;100(6):1553-1567. doi: 10.1007/s00277-021-04514-y. Epub 2021 Apr 17. Ann Hematol. 2021. PMID: 33866396 Free PMC article.
Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.
Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Terävä V, Sinisalo M, Kananen K, Schain F, Castren-Kortegangas P, Järvinen TM, Pisini M, Wahl F, Dixon T, Leval A. Remes K, et al. Among authors: silvennoinen r. PLoS One. 2018 Dec 5;13(12):e0208507. doi: 10.1371/journal.pone.0208507. eCollection 2018. PLoS One. 2018. PMID: 30517181 Free PMC article.
Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V, Silvennoinen R, Anttila P, Säily M, Sankelo M, Putkonen M, Ahonen J, Mahlamäki E, Mäntymaa P, Savolainen ER, Remes K, Jantunen E. Varmavuo V, et al. Among authors: silvennoinen r. Ann Hematol. 2016 Oct;95(10):1653-9. doi: 10.1007/s00277-016-2772-1. Epub 2016 Aug 3. Ann Hematol. 2016. PMID: 27485453 Clinical Trial.
Prognostic significance of esterase gene expression in multiple myeloma.
Kumari R, Majumder MM, Lievonen J, Silvennoinen R, Anttila P, Nupponen NN, Lehmann F, Heckman CA. Kumari R, et al. Among authors: silvennoinen r. Br J Cancer. 2021 Apr;124(8):1428-1436. doi: 10.1038/s41416-020-01237-1. Epub 2021 Feb 3. Br J Cancer. 2021. PMID: 33531688 Free PMC article.
69 results